Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents

• Príomhchruthaitheoirí: Xuanhong Jin (Údar), Yang Pan (Údar), Cheng Cheng (Údar), Hangchen Shen (Údar), Chongya Zhai (Údar), Kailai Yin (Údar), Xinyu Zhu (Údar), Hongming Pan (Údar), Liangkun You (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

BackgroundIn individuals receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience reduced progression-free survival (PFS). However, the effects on overall survival (OS) and the determination of effic...